TY - JOUR
T1 - Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors
AU - Oxbøl, Jytte
AU - Brandt-Larsen, Malene
AU - Schjøth-Eskesen, Christina
AU - Myschetzky, Rebecca Sue Main
AU - El Ali, Henrik H.
AU - Madsen, Jacob
AU - Kjær, Andreas
PY - 2014/3
Y1 - 2014/3
N2 - Introduction: The aim of this study was to synthesize and perform a side-by-side comparison of two new tumor-angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 in vivo using human xenograft tumors in mice. Human radiation burden was estimated to evaluate potential for future use as clinical PET tracers for imaging of neo-angiogenesis. Methods: A 68Ge/68Ga generator was used for the synthesis of 68Ga-NODAGA-E[c(RGDyK)]2. 68Ga and 64Cu labeled NODAGA-E[c(RGDyK)]2 tracers were administrated in nude mice bearing either human glioblastoma (U87MG) or human neuroendocrine (H727) xenograft tumors. PET/CT scans at 3 time points were used for calculating the tracer uptake in tumors (%ID/g), integrin αVβ3 target specificity was shown by blocking with cold NODAGA-E[c(RGDyK)]2, and biodistribution in normal organs were also examined. From biodistribution data in mice human radiation-absorbed doses were estimated using OLINDA/EXM software. Results: 68Ga-NODAGA-E[c(RGDyK)]2 was synthesized with a radiochemical purity of 89%-99% and a specific activity (SA) of 16-153MBq/nmol. 64Cu-NODAGA-E[c(RGDyK)]2 had a purity of 92%-99% and an SA of 64-78MBq/nmol.Both tracers showed similar uptake in xenograft tumors 1. h after injection (U87MG: 2.23 vs. 2.31%ID/g; H727: 1.53 vs. 1.48%ID/g). Both RGD dimers showed similar tracer uptake in non-tumoral tissues and a human radiation burden of less than 10. mSv with an administered dose of 200. MBq was estimated. Conclusion: 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 can be easily synthesized and are both promising candidates for PET imaging of integrin αVβ3 positive tumor cells. 68Ga-NODAGA-E[c(RGDyK)]2 showed slightly more stable tumor retention. With the advantage of in-house commercially 68Ge/68Ga generators, 68Ga-NODAGA-E[c(RGDyK)]2 may be the best choice for future clinical PET imaging in humans.
AB - Introduction: The aim of this study was to synthesize and perform a side-by-side comparison of two new tumor-angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 in vivo using human xenograft tumors in mice. Human radiation burden was estimated to evaluate potential for future use as clinical PET tracers for imaging of neo-angiogenesis. Methods: A 68Ge/68Ga generator was used for the synthesis of 68Ga-NODAGA-E[c(RGDyK)]2. 68Ga and 64Cu labeled NODAGA-E[c(RGDyK)]2 tracers were administrated in nude mice bearing either human glioblastoma (U87MG) or human neuroendocrine (H727) xenograft tumors. PET/CT scans at 3 time points were used for calculating the tracer uptake in tumors (%ID/g), integrin αVβ3 target specificity was shown by blocking with cold NODAGA-E[c(RGDyK)]2, and biodistribution in normal organs were also examined. From biodistribution data in mice human radiation-absorbed doses were estimated using OLINDA/EXM software. Results: 68Ga-NODAGA-E[c(RGDyK)]2 was synthesized with a radiochemical purity of 89%-99% and a specific activity (SA) of 16-153MBq/nmol. 64Cu-NODAGA-E[c(RGDyK)]2 had a purity of 92%-99% and an SA of 64-78MBq/nmol.Both tracers showed similar uptake in xenograft tumors 1. h after injection (U87MG: 2.23 vs. 2.31%ID/g; H727: 1.53 vs. 1.48%ID/g). Both RGD dimers showed similar tracer uptake in non-tumoral tissues and a human radiation burden of less than 10. mSv with an administered dose of 200. MBq was estimated. Conclusion: 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 can be easily synthesized and are both promising candidates for PET imaging of integrin αVβ3 positive tumor cells. 68Ga-NODAGA-E[c(RGDyK)]2 showed slightly more stable tumor retention. With the advantage of in-house commercially 68Ge/68Ga generators, 68Ga-NODAGA-E[c(RGDyK)]2 may be the best choice for future clinical PET imaging in humans.
U2 - 10.1016/j.nucmedbio.2013.12.003
DO - 10.1016/j.nucmedbio.2013.12.003
M3 - Journal article
C2 - 24417983
SN - 0969-8051
VL - 41
SP - 259
EP - 267
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 3
ER -